BOB体育

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 卤鈥�

Investigator

Joanne Lagmay

Ages

1 Year - 30 Years

Sexes

All

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles鈥�

Investigator

Joanne Lagmay

Ages

12 Months - 21 Years

Sexes

All